Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 579 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Coronavirus reports – Part 9: “I am very relieved but I... March 4, 2021 The Grace Project Helps Breast Cancer Survivors Practice Body Acceptance and... July 27, 2021 Single Mom Has To Beg For Rides To Doctor For Son... March 14, 2019 Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with... December 6, 2024 Load more HOT NEWS Company Gives Cancer Patient a New HVAC System After Treatment and... Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline 2020 round-up: Our biggest cancer stories of the year Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in...
